CELZ
What one share of Creative Medical Technology Holdings holds
Biological Products, (No Diagnostic Substances)
We are a commercial stage biotechnology company dedicated to the advancement regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following:
Creative Medical Technology Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.95 |
| Cash and investments | $1.34 |
| Book value | $1.33 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$0.01 | — | −$0.00 | — | −$0.00 |
| 2017 | $0.00 | −$0.03 | — | −$0.01 | — | −$0.02 |
| 2018 | $0.03 | −$3.50 | — | −$0.27 | — | −$0.66 |
| 2019 | $0.02 | −$0.82 | — | −$0.12 | — | — |
| 2020 | $0.00 | −$62.69 | — | −$0.00 | — | — |
| 2021 | $0.03 | $5.61 | — | −$0.68 | — | $1.61 |
| 2022 | $0.01 | −$0.93 | — | −$0.71 | — | — |
| 2023 | $0.01 | −$3.76 | — | −$5.70 | — | $7.53 |
| 2024 | $0.01 | −$3.71 | — | −$3.58 | — | $3.63 |
| 2025 | $0.00 | −$2.52 | — | −$2.46 | — | $2.03 |